A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

drug protocol number

M23-698

drug sponsor

Abbvie

drug study

Upadacitinib (Rinvoq)

drug trial site

King Faisal Specialist Hospital and Research Center (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Jeddah)

drug status

Ongoing

drug phase